A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Trial ID or NCT#
Status
Purpose
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Official Title
A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma
Eligibility Criteria
- - Histologically confirmed mycosis fungoides or Sezary Syndrome. - Stage IB to IVB disease at screening. - Recurrent or refractory disease after at least 1 prior systemic therapy. - Have adequate organ function defined as: - Hepatic: total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine transaminase/aspartate transaminase (ALT/AST) ≤2.5 times the ULN. - Renal: serum creatinine ≤1.5 times the ULN. - Adequate bone marrow reserve: platelets ≥75 * 10^9/Liters (L); absolute neutrophil count (ANC) ≥1.0 * 10^9/L. - At least 30 days must have passed since other treatment for CTCL.
- - Receiving concurrent treatment for CTCL. - Unable to swallow tablets. - Receiving high potency oral or topical steroids. Low potency oral steroid may be permitted in participants who have been on a stable dose for at least 4 weeks prior to screening. Oral or topical antihistamine is allowed. - Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin. - Have a serious concomitant systemic disorder or Human Immunodeficiency Virus (HIV). - Have a serious cardiac condition such as myocardial infarction within past 6 months, angina, or heart disease as defined by the New York Heart Association (NYHA) Class III or IV. - Have electrocardiogram (ECG) abnormalities. - Are pregnant or breastfeeding.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Natalie Viakhireva
6507238949
View on ClinicalTrials.gov